Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Optimizing Outsourcing: A Case Study on Evaluating CDMO Capabilities for API and FD Development

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

02 Jan, 2025, 22:31 GMT

Share this article

Share toX

Share this article

Share toX

A large pharmaceutical company collaborated with DelveInsight to evaluate CDMO companies for API and FD development. DelveInsight provided a comprehensive one-time report benchmarking top contract development and manufacturing organizations based on their R&D, API CDMO manufacturing, and commercialization capabilities. This analysis, leveraging both secondary and primary CI inputs, enabled the client to identify the ideal partner for outsourcing their project.

LAS VEGAS, Jan. 2, 2025 /PRNewswire/ -- DelveInsight, a leading provider of healthcare competitive intelligence, partnered with a large pharmaceutical company seeking to advance their API and FD development and assessed various CDMO companies for outsourcing capabilities. The client aimed to benchmark contract development and manufacturing organizations (CDMOs) to identify the most suitable partner for outsourcing their project. DelveInsight delivered a one-time, in-depth report analyzing the R&D, manufacturing, and commercialization capabilities of key CDMOs, utilizing both secondary and primary competitive intelligence inputs. This strategic evaluation enabled the client to make informed decisions, ensuring alignment with their development goals and achieving optimal outsourcing efficiency.

The global Contract Development and Manufacturing Organization market is set to experience significant growth, driven by its essential role in outsourcing drug development and manufacturing for pharmaceutical companies. According to the latest report by DelveInsight's recent Contract Development Manufacturing Organization (CDMO) forecast report, the CDMO market was valued at USD 100.02 billion in 2021 and is projected to grow at a CAGR of 6.25%, reaching USD 143.87 billion by 2030. 

This growth is fueled by the increasing prevalence of cancer, genetic disorders and rare conditions, which have spurred demand for innovative therapies and orphan drugs. For example, the GLOBOCAN 2022 study reported approximately 20 million new cancer cases and 9.7 million cancer deaths globally, while nearly 475 million people worldwide are affected by rare diseases. These trends underscore the critical role of CDMOs in providing scalable solutions for pharmaceutical companies addressing unmet medical needs. 

The United States remains a key hub for pharmaceutical development outsourcing; however, the APAC region is increasingly becoming the preferred market for CDMO growth. This is mainly due to the region's more cost-effective manufacturing than North America and Europe. Furthermore, significant funding investments and the proximity of pharmaceutical research centers to universities contribute to this shift.

Strategic partnerships and acquisitions, coupled with the impact of the COVID-19 pandemic, have further propelled the CDMO market growth. Leading pharmaceutical companies like Moderna and Pfizer collaborated with CDMOs such as Catalent and Lonza to meet the surge in vaccine demand during the pandemic. Additionally, industry consolidation has strengthened capabilities, with acquisitions like Thermo Fisher's purchase of Brammer Bio for USD 1.7 billion and Merck's acquisition of AmpTec to bolster mRNA manufacturing. Such initiatives have highlighted the importance of CDMOs in accelerating drug development and commercialization, especially during global health crises.

The CDMO market is dominated by key players offering a range of expertise, including Patheon (Thermo Fisher Scientific), Catalent, Inc., Laboratoire Elaiapharm, The Lubrizol Corporation, Cambrex Corporation, Recipharm (EQT), Merck & Co., Inc., AGC Biologics, Nerpharma S.r.l, Pfizer CenterOne (Pfizer Inc), EMERGENT, Onyx Scientific Limited, Lonza, Siegfried Holding AG, CordenPharma International, FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Delpharm, Center for Breakthrough Medicines, and WuXi Biologics. The CDMO Market report analyzed the companies working in this domain in detail. 

Download the Sample Report to Explore Future Trends in the Contract Development and Manufacturing Organization (CDMO) market.

DelveInsight's Comprehensive Methodology for Evaluating CDMO Capabilities

DelveInsight employed a comprehensive methodology to assist clients in identifying and evaluating potential Contract Development and Manufacturing Organizations (CDMOs) that aligned with their project requirements and strategic goals. The process begins with a thorough search and identification of CDMOs in geographies of interest, ensuring the client has access to the most suitable partners. Competitive Intelligence (CI) is gathered through secondary sources and enriched with primary research conducted via interviews and surveys tailored to the client's needs. Additionally, the project's current status is meticulously analyzed to estimate potential timelines for completion, providing clarity on project progression.

Key logistical aspects such as equipment ordering, delivery schedules, and the installation and validation of machinery are carefully planned and managed. Active Pharmaceutical Ingredients (APIs) availability is assessed to ensure seamless project execution while potential partnerships with other API suppliers are explored and evaluated. Furthermore, detailed reviews of sterilization processes are conducted to maintain high-quality standards and compliance.

DelveInsight also identified and analyzed potential challenges and barriers to the project, offering strategic solutions to mitigate risks. Manufacturing plants were evaluated based on location, providing insights into logistical and strategic advantages. Finally, the manufacturing status and capabilities of identified CMOs was thoroughly assessed, ensuring the client has a clear understanding of their operational readiness and capacity to meet project demands. This structured approach empowered DelveInsight to deliver impactful insights and drive successful outcomes for their clients.

Comprehensive Results and Strategic Insights for CDMO Selection:

DelveInsight meticulously crafted a robust framework to address the client's research needs, delivering detailed CDMO profiles that streamlined the evaluation process. This framework offered the client a comprehensive understanding of potential CDMO partners, shedding light on their strengths, weaknesses, and core capabilities facilitating informed decisions regarding project outsourcing.

An in-depth analysis was conducted to assess the research and development technologies, manufacturing capabilities, and commercial potential of prospective CDMOs. This evaluation offered critical insights into each partner's technological expertise, production capacity, and long-term business viability, ensuring alignment with the client's strategic objectives and market aspirations.

Additionally, a comprehensive competitive assessment was performed to analyze the market positioning and performance of various CDMOs. This analysis provided a benchmark against industry standards, enabling the client to identify the most capable and competitive partner for outsourcing Active Pharmaceutical Ingredient (API) and Finished Dosage (FD) development. The delivery of evidence-based insights equipped the client with a robust strategic foundation to navigate regulatory and market complexities, facilitating seamless market entry and ensuring long-term success.

Why Choose DelveInsight?

DelveInsight is an expert in providing comprehensive frameworks that help pharmaceutical companies streamline their research processes and make informed decisions regarding CDMO services. With in-depth knowledge of R&D technologies, manufacturing capabilities, and commercial potential, DelveInsight offers valuable insights into the strengths and weaknesses of potential partners. The firm's expertise in conducting competitive assessments allows clients to benchmark companies of interest against industry standards, ensuring they select the most capable and competitive partners for their strategic interests. Additionally, DelveInsight's evidence-based approach provides strategic support, helping clients align their strategies with market realities and regulatory requirements for long-term success.

Contact us today to see how we can support your needs and discuss potential opportunities for collaboration. Request a Proposal Now!

Partner Identification for biotech, a Service that Helps Identify, Acquire, Measure, and Manage Collaborations: Fostering long-term relationships among pharmaceutical and biotech companies is essential for creating value for all stakeholders, but navigating the process can be complex. DelveInsight's partnering services provide strategic opportunities for companies to collaborate on projects aligned with their specific interests. Through our extensive networks and a comprehensive partnering methodology, we carefully scout ideal candidates for partnerships by evaluating unmet needs, validating scientific and business perspectives, and ensuring a strategic fit. This approach enables our clients to build value-based relationships, overcome organizational barriers, and secure successful, long-term collaborations in their respective markets.

Let's discuss how our strategic partner identification services can help you acquire, measure, and manage the right collaborations for your business growth.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

Modal title

Also from this source

DHODH Inhibitors Market Forecast to Reach New Heights by 2034 Owing to the Expanding Applications in Oncology and Autoimmune Diseases | DelveInsight

DHODH Inhibitors Market Forecast to Reach New Heights by 2034 Owing to the Expanding Applications in Oncology and Autoimmune Diseases | DelveInsight

DelveInsight's DHODH Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding ...

BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsight

BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsight

DelveInsight's BAFF- and APRIL-targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.